janvier 28, 2023


Dernières nouvelles et nouvelles du monde de 7 Seizh sur les affaires, les sports et la culture. Nouvelles vidéo. Nouvelles des États-Unis, d'Europe, d'Asie-Pacifique, d'Afrique, du Moyen-Orient, d'Amérique.

Ireland awaits another Covid-19 vaccine after EMA approves Novavax

Ireland is ready to get another Covid-19 vaccine after the European Medicines Agency gave the green light to Novavax.

Reland could withdraw about 1.1 million doses of the vaccine under a purchase agreement with the European Union.

It is the fifth vaccine recommended in the European Union to prevent Covid-19.

It is a protein-based vaccine and, along with those already authorized, will support vaccination campaigns in European Union member states during a critical phase of the epidemic.

After a thorough evaluation, the EMA’s Committee on Human Medicines (CHMP) unanimously concluded that the data on the vaccine were robust and meet EU standards for efficacy, safety and quality.

Results from two major clinical trials found that a vaccine known as Nuvaxovid was effective in preventing Covid-19 in people as young as 18 years old.

The Indo Daily: Booster Vaccines and the Ethical Dilemma – Are They a Global First Problem?

Listen on Spotify

The studies included more than 45,000 people in total. In the first study, about two-thirds of the participants received the vaccine while the others were given a placebo (dummy) injection; In the other study, participants were evenly split between Nuvaxovid and a placebo. People did not know if they had received Nuvaxovid or a placebo.

The first study, conducted in Mexico and the United States, found a 90.4% reduction in the number of symptomatic Covid-19 cases from 7 days after the second dose in people who received Nuvaxovid (14 out of 17,312 people) compared to those given. Placebo (63 out of 8,140 people). This means that the vaccine had an potency of 90.4 pieces in this study.

READ  Le plus grand objet jamais construit en Irlande doit être expédié aux États-Unis

The second study, conducted in the UK, also showed a similar reduction in the number of symptomatic Covid-19 cases in people who received Nuvaxovid (10 out of 7,020 people) compared to people treated with a placebo (96 out of 7,019 people); In this study, the effectiveness of the vaccine was 89.7 pieces..

Taken together, the results of the two studies show that the effectiveness of the Nuvaxovid vaccine is about 90 pieces. The original SARS-CoV-2 strain and some variants of concern such as Alpha and Beta were the most common viral strains circulating when studies were ongoing. There is currently limited data on the effectiveness of Nuvaxovid against other variants of concern, including Omicron.

Side effects observed with Nuvaxovid in studies were usually mild or moderate and resolved within two days after vaccination. The most common were soreness or pain at the injection site, fatigue, muscle aches, headache, general feeling of malaise, joint pain, and nausea or vomiting.

She said the vaccine’s safety and efficacy will continue to be monitored as it is used across the European Union, through the European Union’s pharmacovigilance regime and additional studies by the company and European authorities.

we visited Covid-19 vaccine dashboard For updates on the start of the vaccination program and the rate of coronavirus cases in Ireland